Polymorphisms in the large subunit of human RNA polymerase II as target for allele-specific inhibition.
The lack of specificity of cancer treatment causes damage to normal cells as well, which limits the therapeutic range. To circumvent this problem one would need to use an absolute difference between normal cells and cancer cells as therapeutic target. Such a difference exists in the genome of all individuals suffering from a tumor that is characterized by loss of genetic material [loss of heterozygosity (LOH)]. Due to LOH, the tumor is hemizygous for a number of genes, whereas the normal cells of the individual are heterozygous for these genes. Theoretically, polymorphic sites in these genes can be utilized to selectively target the cancer cells with an antisense oligonucleotide, provided that it can discriminate the alleles and inhibit gene expression. Furthermore, the targeted gene should be essential for cell survival, and 50% gene expression sufficient for the cell to survive. This will allow selective killing of cancer cells without concomitant toxicity to normal cells. As an initial step in the experimental test of this putative selective cancer cell therapy, we have developed a set of antisense phosphorothioate oligonucleotides which can discriminate the two alleles of a polymorphic site in the gene encoding the large subunit of RNA polymerase II. Our data show that the exact position of the antisense oligonucleotide on the mRNA is of essential importance for the oligo-nucleotide to be an effective inhibitor of gene expression. Shifting the oligonucleotide position only a few bases along the mRNA sequence will completely abolish the inhibitory activity of the antisense oligonucleotide. Reducing the length of the oligonucleotides to 16 bases increases the allele specificity. This study shows that it is possible to design oligonucleotides that selectively target the matched allele, whereas the expression level of the mismatched allele, that differs by one nucleotide, is only slightly affected.
ten Asbroek
A L
AL
Neurozintuigen Laboratory, Academic Medical Center, PO Box 22700, 1000 DE Amsterdam, The Netherlands.
Fluiter
K
K
van Groenigen
M
M
Nooij
M
M
Baas
F
F
D000483:Alleles; D001483:Base Sequence; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015316:Genetic Therapy; D006801:Humans; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000235:genetics / Q000628:therapy; D016376:Oligonucleotides, Antisense / Q000235:genetics / Q000494:pharmacology; D011110:Polymorphism, Genetic; D012319:RNA Polymerase II / Q000235:genetics*
D004791:Enzyme Inhibitors; D016376:Oligonucleotides, Antisense; D012319:RNA Polymerase II